Prof Andrew Wei co-leads the acute myeloid leukemia program at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital in Melbourne, Australia. He is a Metcalf Family research fellow and NHMRC investigator at WEHI (the Walter and Eliza Hall Institute of Medical Research) whose laboratory investigates novel approaches to treat AML.
His interests include BH3-mimetics, targeting MRD and the role of TP53 in AML. Prof Wei has been principal investigator for numerous commercially sponsored and investigator-initiated clinical trials and sits on the steering committee for multiple global advisory boards developing new drugs in the field of AML. Prof Wei has also successfully mentored numerous clinical fellows to lead nationwide clinical trials in AML.